The University of Osaka · 의학
Yuwei Liu 교수의 연구실은 주로 표적 방사성동위원소 치료(Theranostics)를 중심으로, FAP(섬유아세포 활성화 단백질) 및 NIS(나트륨 요오도화물 회수수용체)를 표적으로 하는 방사성 약물 개발에 집중하고 있습니다. 특히 알파선 방출체인 211At-NaAt를 활용한 갑상선암 치료와 FAPI 기반 방사성 치료제의 최적화를 통해 고감도 진단과 정밀한 종양 억제를 동시에 실현하고자 합니다. 생체 내 분포, 독성 평가 및 병변 조절 메커니즘을 종합적으로 분석함으로써 임상 적용 가능성을 높이는 데 목표를 두고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
This study suggested the possible application of FAPI radioligand therapy in FAP-expressing pancreatic cancer. Further evaluation is necessary to find the best radionuclide with shorter half-life, as well as the combination with therapies targeting tumour cells directly.
We recently reported the dose-dependent therapeutic effect of <sup>211</sup>At-NaAt in differentiated thyroid cancer xenograft models. In the present study, we evaluated the radiation-induced toxicity of <sup>211</sup>At-NaAt using detailed hematological, biochemical, and histological analyses. Biodistribution of <sup>211</sup>At-NaAt was measured in normal ICR mice (n = 12), absorbed doses in the major organs were calculated. Groups of ICR mice (n = 60) were injected with 0.1 MBq or 1 MBq of <s
Abstract Purpose Fibroblast activation protein (FAP), which has high expression in cancer-associated fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study used 64 Cu and 225 Ac-labelled FAP inhibitors (FAPI-04) for a FAP-expressing pancreatic cancer xenograft imaging and therapy. However, the optimal therapeutic radionuclide for FAPI still needs to be further investigated. In this study, we evaluated the therapeutic effects of beta-emitter( 177 Lu)-labelled F
98 Purpose: Astatine(211At), an alpha-emitter with similar chemical properties to iodine, is expected to have a better therapeutic effect compared to 131I (beta-emitter). In the previous study, we revealed the dose-dependent therapeutic effect of 211At-NaAt solution by K1-NIS xenograft mice. In this study, we aimed to prove the better therapeutic effect of 211At-NaAt than 131I-NaI in differentiated thyroid cancer model. Methods: Colony assay and DNA double-strand break (DSB) assay were performe
1224 Purpose: We have recently reported the dose-dependent therapeutic effect of 211At-NaAt in differentiated thyroid cancer xenograft models. In this study, we evaluated the radiation-induced toxicity of 211At-NaAt using detailed hematological, biochemical, and histological analyses. Methods: Biodistribution of 211At-NaAt was measured in the normal ICR mice (n = 9, 38.2 ± 1.1 g), and the absorbed doses in the major organs were calculated. ICR mice groups (n = 60, 38.3 ± 1.9 g) were injected wi
1256 Purpose: An alpha-emitter, astatine(211At), can be used for the targeted alpha therapy of differentiated thyroid cancer. We have shown the dose-dependent treatment effect of 211At-NaAt solution using K1-NIS xenograft mice by single intravenous administration. In this study, we evaluated the therapeutic effect of repeated administration of 211At-NaAt solution to achieve the better tumor growth control against the radiation-induced toxicity of for the clinical application. Methods: Total of
